Atherosclerosis and the mouse: A decade of experience

Annals of Medicine

Volumn 29, Issue 3, 1997, Pages 193-198

  Plump, Andrew ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Lipoprotein disorders; Mouse genetics

Indexed keywords

LIPOPROTEIN;

ANIMAL MODEL; ATHEROSCLEROSIS; GENETICS; MOUSE; NONHUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030879370     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899708999336     Document Type: Short Survey

References (48)

1. Jokinen M, Clarkson T, Prichard R. Animal models in atherosclerosis research. Exp Mol Pathol 1985; 42: 1-28.
2. Paigen B, Morrow A, Holmes P, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985; 57: 65-73.
3. Paigen B, Ishida B, Verstuyft J, Winters R, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis 1990; 10: 316-23.
4. Paigen B, Mitchell D, Reue K, Morrow A, Lusis A, Le Boeuf R. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc Natl Acad Sci USA 1987; 84: 3763-7.
5. Paigen B, Nesbitt M, Mitchell D, Albee D, Leboeuf R. Ath-2, a second gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Genetics 1989; 122: 163-8.
6. Stewart-Phillips J, Lough R, Skamene E. Ath-3, a new gene for susceptibility to atherosclerosis in mice. Clin Invest Med 1989; 12: 121-6.
7. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CA, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, Vol. 2, 7th edn. New York: McGraw-Hill, 1995: 1981-2030.
8. Rubin EM, Krauss R, Spangler E, Verstuyft J, Clift S. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991; 353: 265-7.
9. Breslow JL. Familial disorders of high density lipoprotein metabolism. In: Scriver CA, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, Vol. 2, 7th edn. New York: McGraw-Hill, 1995: 2031-52.
10. 3. J Biol Chem 1989; 264: 6488-94.
11. Rubin E, Ishida B, Clift S, Krauss R. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci USA 1991; 88: 434-438.
12. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984; 25: 1017-58.
13. Brinton E, Eisenberg S, Breslow J. Human HDL cholesterol levels are determined by apo A-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic, and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994; 14: 707-20.
14. Deeb S, Takata K, Peng R, Kajiyama G, Albers J. A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. Am J Hum Genet 1990; 46: 822-7.
15. Cheung M, Albers J. Distribution of high density lipoproteins with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res 1982; 26: 747-53.
16. Barbaras R, Puchois P, Fruchart J, Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpAl particles but not by LpAl: All particles. Biochem Biophys Res Commun 1987; 142: 63-9.
17. Cheung M, Brown B, Wolf A, Albers J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991; 32: 383-94.
18. Schultz J, Verstuyft J, Gong E, Nichols A, Rubin E. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993; 365: 762-4.
19. Warden C, Hedrick C, Qiao J-H, Castellani L, Lusis A. Atherosclerosis in mice overexpressing apolipoprotein A-II. Science 1993; 261: 469-72.
20. Scanu A, Lawn R, Berg K. Lipoprotein (a) and atherosclerosis. Ann Intern Med 1991; 115: 209-18.
21. Lawn R, Wade D, Hammer R, Verstuyft J, Rubin E. Atherogenesis in transgenic mice expressing human apolipoprotein (a). Nature 1992; 360: 670-1.
22. Linton M, Farese R, Chiesa G, et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein (a). J Clin Invest 1993; 92: 3029-37.
23. Callow M, Stoltzfus L, Lawn R, Rubin E. Expression of human apolipoprotein B and assembly of lipoprotein (a) in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 2130-4.
24. Callow M, Verstuyft J, Tangirala R, Palinski W, Rubin E. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 1995; 96: 1639-46.
25. Purcell-Huynh D, Farese R, Johnson D, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 1995; 95: 2246-57.
26. Marotti K, Castle C, Boyle T, Lin A, Murray R, Melchior G. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364: 73-4.
27. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing a cholesteryl ester transfer protein transgene. J Clin Invest 1995; 96: 2071-4.
28. Mahley RW, Rail S Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CA, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, Vol. 2, 7th edn. New York: McGraw-Hill, 1995: 1953-80.
29. van den Maagdenberg A, Hofker M, Krimpenfort P, et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993; 268: 10540-5.
30. van Vlijmen J, van Maagdenberg A, Gijbels M, et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994; 93: 1403-10.
31. Fazio S, Lee Y, Sheng Z, Rall Jr S. Type III hyperlipoproteinemia phenotype in transgenic mice expressing dysfunctional apolipoprotein E. J Clin Invest 1993; 92: 1497-503.
32. Fazio S, Sanan D, Lee Y, Ji Z, Mahley R, Rall S Jr. Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E(arg 112, cys 142). Arterioscler Thromb 1994; 14: 1873-9.
33. Williamson R, Lee D, Hagaman J, Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci USA 1992; 88: 7134-8.
34. Plump AS, Hayek T, Walsh A, Breslow JL. Diminished HDL cholesterol ester flux in apo A-I-deficient mice. Circulation 1993; 88: 2266a.
35. Piedrahita J, Zhang S, Hagaman J, Oliver P, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992; 89: 4471-5.
36. Plump A, Smith J, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-53.
37. Zhang S, Reddick R, Piedrahita J, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-71.
38. Li H, Reddick R, Maeda N. Lack of apo A-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13: 1814-21.
39. Voyiaziakis E, Plump A, Rubin E, Breslow J, Huang L-S. Low HDL associated with mouse apo A-I deficiency increases atherosclerosis in human apo B transgenic mice. Circulation 1996; 94 (Suppl): 633 (Abstr).
40. Hughes S, Verstuyft J, Ighani S, Rubin E. Lack of apolipoprotein A-I in human apolipoprotein B transgenic mice results in greater susceptibility to diet induced atherosclerosis. Circulation 1996; 94 (Suppl): 633 (Abstr).
41. Mahley R. Apolipoprotein E: cholesterol transport protein with an expanding role in cell biology. Science 1988; 240: 622-30.
42. Plump A, Breslow J. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr 1995; 15: 495-518.
43. Nakashima Y, Plump A, Raines E, Breslow J, Ross R. Apo E-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994; 14: 133-40.
44. Reddick R, Zhang S, Maeda N. Arteriosclerosis in mice lacking apo E. Arterioscler Thromb 1994; 14: 141-7.
45. Plump AS, Scott C, Breslow J. Human apolipoprotein A-I gene expression increases high density lipoproteins and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994; 91: 9607-11.
46. Paszty C, Maeda N, Verstuyft J, Rubin E. Apolipoprotein Al transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899-903.
47. Linton M, Atkinson J, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995; 267: 1034-7.
48. Kashyap V, Santamarina-Fojo S, Brown D, et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest 1995; 96: 1612-20.